Scientific summaries and reflections of the latest scientific evidence are shared via a newsletter on a quarterly basis. The goal is to help our most valued customers stay up to date about the latest VNS clinical evidence in an objective and simple way, as we know that many have too much on their plate to be able to do this by themselves.
Jan 2023
Clinical Review 2022
Within the past two decades, the first United States Food and Drug Administration (FDA)-approved neuromodulation therapy for drug-resistant epilepsy (DRE), namely vagus nerve stimulation (VNS) Therapy®, has risen to be a well-accepted and promising treatment option for patients with DRE.
Following this trend, the number of publications on the efficacy of VNS Therapy in DRE has increased. According to a bibliometric analysis of published studies within the field of VNS between the years 2000 and 2021, the highest number of citations was reached in 2021 (7098 citations in total) and the most significant number of yearly publications was observed during the year 2020 (270 publications in total). Furthermore, the two primary research areas were the mechanisms involved in the neuromodulatory function of VNS and the clinical implementation of VNS for treating different diseases outside the field of neurology.
This newsletter aims to provide scientific and clinical updates on the efficacy of VNS Therapy in DRE and difficult-to-treat depression based on peer-reviewed published clinical studies from 2022. The annual newsletter starts with the top three clinical summaries (listed as follows), describing some of the most important VNS studies that were published during 2022, as selected by our medical affairs team.Subsequently, the remaining summaries and critical reflections that have been written based on publications from 2022 are listed and divided into sub-groups of different categories.
Norwegian population-based study of long-term effects, safety, and predictors of response of vagus nerve stimulation treatment in drug-resistant epilepsy: The NORPulse study.
The role of vagus nerve stimulation in genetic etiologies of drug-resistant epilepsy: a meta-analysis.
Rapid titration of VNS therapy reduces time-to-response in epilepsy